S.Africa says J&J, Pfizer, Moderna vaccines those for "immediate use"

South Africa's health minister said on Tuesday that government advisers had organised COVID-19 vaccines into three groups and those considered for "immediate use" were the Johnson & Johnson (J&J), Pfizer and Moderna shots.

Reuters | Cape Town | Updated: 23-02-2021 22:11 IST | Created: 23-02-2021 22:10 IST
S.Africa says J&J, Pfizer, Moderna vaccines those for "immediate use"
Representative Image Image Credit: ANI

South Africa's health minister said on Tuesday that government advisers had organised COVID-19 vaccines into three groups and those considered for "immediate use" were the Johnson & Johnson (J&J), Pfizer and Moderna shots. The country started rolling out the J&J vaccine in a research study targeting healthcare workers last week and hopes to receive Pfizer doses in the coming months.

It has paused AstraZeneca vaccinations because of a small trial showing the British company's shot offered minimal protection against mild to moderate illness caused by the dominant local coronavirus variant. Health Minister Zweli Mkhize said the government had placed "huge orders on J&J and Pfizer which will be finalised in the next few days and announced when concluded", adding that discussions with Moderna were ongoing.

Mkhize said the Ministerial Advisory Committee on vaccines had placed Russia's Sputnik V vaccine and alternatives from China's Sinopharm and Sinovac in a second group where South Africa is interested but requires more technical information. Non-disclosure agreements had been signed with manufacturers of vaccines in the second group and negotiations were advanced, he added, saying: "They have offered several millions of vaccines subject to the finalisation of the outstanding information and price negotiation."

A third group where vaccines "may not be suitable for immediate use in South Africa" includes the AstraZeneca and Novavax vaccines. South Africa has recorded almost half of the COVID-19 deaths and over a third of confirmed infections in all of Africa, but has lagged wealthier nations in its immunisation drive.

The government plans to vaccinate 40 million people, or two-thirds of the population. Mkhize said the next batch of 80,000 J&J doses for the research study would arrive on Saturday.

The health and finance ministries had agreed on a mechanism that would compensate any citizen who might suffer an adverse effect from the J&J or Pfizer vaccines, he added. Mkhize said South Africa would be selling, not donating, its stock of AstraZeneca shots to the African Union.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Addressing conflict-related sexual violence at long last

... ...

Why unequal access to coronavirus vaccines is a threat to us all

... ...

India’s love affair with fossil fuels: the path to sustainable development?

... ...

Videos

Latest News

Reuters US Domestic News Summary

Following is a summary of current US domestic news briefs. Hours-long reading of legislation delays debate on Bidens 1.9 trillion COVID-19 billThe U.S. Senate voted on Thursday to take up President Joe Bidens 1.9 trillion coronavirus aid bi...

Saudi asks India to use cheap oil it bought last year to cool prices

International oil prices rose after OPEC and its allies ignored Indias plea to ease production control, with Saudi Arabia asking New Delhi to instead use oil it bought at rock bottom rates last year.Brent crude, the most widely used benchma...

Ikgomotseng learners encouraged to be environmentally conscious

Deputy Minister of Environment, Forestry and Fisheries, Makhotso Sotyu, has encouraged learners of the Ikgomotseng community to be environmentally conscious and ensure their community is free of litter.The Deputy Minister was addressing lea...

Reuters Health News Summary

Following is a summary of current health news briefs. What you need to know about the coronavirus right nowHeres what you need to know about the coronavirus right now Vaccine confidence grows as side-effect worries fade Britain tells EU Vac...

Give Feedback